erlotinib has been researched along with pulmicort in 3 studies
| Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (pulmicort) | Trials (pulmicort) | Recent Studies (post-2010) (pulmicort) |
|---|---|---|---|---|---|
| 221 | 0 | 180 | 4,995 | 1,638 | 1,785 |
| Protein | Taxonomy | erlotinib (IC50) | pulmicort (IC50) |
|---|---|---|---|
| Glucocorticoid receptor | Homo sapiens (human) | 0.0026 | |
| Progesterone receptor | Homo sapiens (human) | 0.028 | |
| Glucocorticoid receptor | Rattus norvegicus (Norway rat) | 0.0029 | |
| Glycine receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 0.0045 | |
| Mineralocorticoid receptor | Homo sapiens (human) | 0.014 | |
| Matrix metalloproteinase-9 | Homo sapiens (human) | 1.989 | |
| Androgen receptor | Rattus norvegicus (Norway rat) | 1.1725 | |
| Glycine receptor subunit beta | Rattus norvegicus (Norway rat) | 0.0045 | |
| Glycine receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | 0.0045 | |
| Glycine receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | 0.0045 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for erlotinib and pulmicort
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for erlotinib and pulmicort
| Article | Year |
|---|---|
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |